|
|
 |
|
Viewing report
|
|
|
|
Competitor Analysis - Janus Kinase (JAK) Inhibitors 2010
La Merie Publishing, Oct 2010, Pages: 29
The present Competitive Intelligence Report about new developments in the pipeline of inhibitors of the janus-associated kinase (JAK) provides a competitor evaluation in the field of active R&D projects from preclinical stages up to advanced clinical phases of JAK Inhibitors as of October 2010. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
As cytokines play pivotal roles in immunity and inflammation, targeting of cytokines and their receptors represents an effective means of treating such diseases. Janus kinases (JAK) are a small family of receptor-associated kinases, that together with signal transducers and activators of transcription (STAT), provide a rapid signalling pathway for cytokines. Four JAKs have been identified: JAK1, JAK2, JAK3 and tyrosine kinase 2 (Tyk2). JAK3 has attracted much attention as an anti-inflammatory drug target because of its restricted hematopoietic tissue expression and because of its specific association with the common gamma chain of the interleukin-2 (IL-2) receptor which is shared by the receptors for IL-4, IL-7, IL-9, IL-15 and IL-21. Quite a number of companies are developing selective JAK3 inhibitors as JAK3 appears not to have functions outside of hematopoetic cells. Pfizer leads the field with evaluation of JAK3 inhibition in a number of inflammatory diseases including rheumatoid arthritis, ulcerative colitis, Crohn's disease and psoriasis. JAK2 gain-of-function mutations (JAK2V617F) underlie a subset of disorders collectively referred to as myeloproliferative disorders. The most advanced JAK2 inhibitors are also being evaluated in phase II trials for myelofibrosis, polycythemia vera and essential thrombocythemia.
The report includes a compilation of current active projects in research and development of selective and multi-kinase inhibitors incl. JAK-2 and JAK-3 inhibitors, for the treatment of myelofibrosis, polycythemia vera, psoriasis, rheumatoid arthritis and other inflammatory diseases. In addition, the report lists company-specific pipelines of JAK inhibitors. Competitor projects are listed in a tabular format providing Information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Competitor Analysis: Janus Kinase (JAK) Inhibitors
Competitor Analysis - p38 MAPK Inhibitors 2010
Competitor Analysis - Sphingosine-1-Phosphate (S1P)
Competitor Analysis - Interleukin-1 (IL-1) and Receptor (IL-1R) Antagonists
R&D Trends: Psoriasis - Pipeline outlook following withdrawal of key regulatory filing
Rheumatoid Arthritis Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Brief Report: Interleukin-17 (IL-17R) and IL-17 Receptor Antagonists
Autoimmune Disorders Therapeutics Market to 2017 - Launch of Gilenya and Benlysta to Drive the Growth of Multiple Sclerosis and Systemic Lupus Erythematosus Therapeutic Segments
Oncology Pipeline Database
Competitor Analysis: Protein Kinase C (PKC) Inhibitors
|
|
|
|
